Abstract
Melanoma in situ (MIS) is a form of radial growth phase melanoma in which the proliferation of malignant cells is confined to the epidermis. Histologic features are invaluable in recognition of MIS. Regression occurs when the host’s immune system attacks the primary melanocytic tumor cells via tumor infiltrate lymphocytes, resulting in a fibrotic component. Various criteria have been proposed to assess the extent of histologic regression. Some authors define regression based on histologic features of the dermis, which is inappropriate for MIS. Specific dermatoscopic findings of regression in MIS have been reported including peppering, grey–blue areas, white areas, and blue-whitish veils. Many studies assess the impact of histologic regression on invasive melanoma prognosis, but no studies to-date have considered the effect of histologic regression exclusively in patients with MIS. The literature to-date does not suggest evaluation and management should be modified if histologic regression is present in MIS. Studies specifically investigating the effect of histologic regression on MIS prognosis are needed to inform evidence-based practices.
Similar content being viewed by others
References
Aung PP, Nagarajan P, Prieto VG (2017) Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. Lab Investig 97:657–668. https://doi.org/10.1038/labinvest.2017.8
Gershenwald JE, Scolyer RA (2018) Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 25:2105–2110
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590
Higgins HW, Lee KC, Galan A, Leffell DJ (2015) Melanoma in situ: part I. Epidemiology, screening, and clinical features. J Am Acad Dermatol 73:181–190
Nikolaou V, Stratigos AJ (2014) Emerging trends in the epidemiology of melanoma. Br J Dermatol 170:11–19. https://doi.org/10.1111/bjd.12492
Swetter SM, Tsao H, Bichakjian CK et al (2019) Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 80:208–250. https://doi.org/10.1016/j.jaad.2018.08.055
Ehrsam E, Kallini JR, Lebas D et al (2016) Fully regressive melanoma a case without metastasis. J Clin Aesthet Dermatol 9:42–46
Ribero S, Moscarella E, Ferrara G et al (2016) Regression in cutaneous melanoma: a comprehensive review from diagnosis to prognosis. J Eur Acad Dermatology Venereol 30:2030–2037
Guitart J, Lowe L, Piepkorn M et al (2002) Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 138:603–608. https://doi.org/10.1001/archderm.138.5.603
Higgins HW, Lee KC, Galan A, Leffell DJ (2015) Melanoma in situ: Part II. Histopathology, treatment, and clinical management. J Am Acad Dermatol 73:193–203. https://doi.org/10.1016/j.jaad.2015.03.057
Linos E, Swetter SM, Cockburn MG et al (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129:1666–1674. https://doi.org/10.1038/jid.2008.423
Welch HG, Woloshin S, Schwartz LM (2005) Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 331:481. https://doi.org/10.1136/bmj.38516.649537.E0
Mocellin S, Nitti D (2011) Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist 16:896–903. https://doi.org/10.1634/theoncologist.2010-0340
Mu EW, Quatrano NA, Yagerman SE et al (2018) Evaluation of MITF, SOX10, MART-1, and R21 immunostaining for the diagnosis of residual melanoma in situ on chronically sun-damaged skin. Dermatol Surg 44:933–938. https://doi.org/10.1097/DSS.0000000000001493
Bartoli C, Bono A, Clemente C et al (1996) Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer 77:888–892. https://doi.org/10.1002/(sici)1097-0142(19960301)77:5<888:aid-cncr12>3.0.co;2-#
Lallas A, Longo C, Manfredini M et al (2018) Accuracy of DERMOSCOPIC CRITERIA FOR THE DIAGNOSIS OF MELANOMA IN SITu. JAMA Dermatol 154:414–419. https://doi.org/10.1001/jamadermatol.2017.6447
Seidenari S, Bassoli S, Borsari S et al (2012) Variegated dermoscopy of in situ melanoma. Dermatology 224:262–270. https://doi.org/10.1159/000338696
Seidenari S, Ferrari C, Borsari S et al (2010) Reticular grey-blue areas of regression as a dermoscopic marker of melanoma in situ. Br J Dermatol 163:302–309. https://doi.org/10.1111/j.1365-2133.2010.09821.x
Ribero S, Galli F, Osella-Abate S et al (2019) Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. J Am Acad Dermatol 80:99–105.e5. https://doi.org/10.1016/j.jaad.2018.06.054
Shai A, Avinoach I, Sagi A (1994) Metastatic malignant melanoma with spontaneous and complete regression of the primary lesion. Case report and review of the literature. J Dermatol Surg Oncol 20:342–345. https://doi.org/10.1111/j.1524-4725.1994.tb01635.x
Smoller BR (2006) Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol 19(Suppl 2):S34–40. https://doi.org/10.1038/modpathol.3800508
Zurac S, Neagu M, Constantin C et al (2016) Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett 11:3354–3360. https://doi.org/10.3892/ol.2016.4391
Kang S, Barnhill RL, Mihm MCJ, Sober AJ (1993) Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol 20:126–129. https://doi.org/10.1111/j.1600-0560.1993.tb00228.x
Bassoli S, Borsari S, Ferrari C et al (2011) Grey-blue regression in melanoma in situ—evaluation on 111 cases. J Skin Cancer 2011:1–5. https://doi.org/10.1155/2011/180980
Alarcon I, Carrera C, Palou J et al (2014) Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions. Br J Dermatol 170:802–808. https://doi.org/10.1111/bjd.12678
Mikkelsen J, Hagen Wagenblast AL, Behrendt N, Lock-Andersen J (2017) Melanoma in situ with in-transit metastases. JPRAS Open 11:37–42. https://doi.org/10.1016/j.jpra.2017.01.006
Sun SH, Peters SB, Howard JH (2017) Sentinel lymph node melanosis: a report of two cases of regressed melanoma metastases. SM Dermatol J 3:1–3. https://doi.org/10.36876/smdj.1014
Zugna D, Senetta R, Osella-Abate S et al (2018) Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. Br J Cancer 118:398–404. https://doi.org/10.1038/bjc.2017.397
Funding
No funding was received.
Author information
Authors and Affiliations
Contributions
AK had the idea for the article. AMC performed the initial literature search and data analysis. AMC drafted the initial draft. PCA performed an additional literature search and secondary data analysis. PCA and AK revised the work.
Corresponding author
Ethics declarations
Conflicts of interest
Alexander M. Cartron, BS, Paola C. Aldana, MD, and Amor Khachemoune, MD, FAAD, FACMS declare that they have no potential conflicts of interest to disclose.
Ethical approval
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article contains original unpublished work that is not being submitted for publication or presentation elsewhere.
Rights and permissions
About this article
Cite this article
Cartron, A.M., Aldana, P.C. & Khachemoune, A. Reporting regression with melanoma in situ: reappraisal of a potential paradox. Arch Dermatol Res 313, 65–69 (2021). https://doi.org/10.1007/s00403-020-02106-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-020-02106-w